Omentin as a novel biomarker of metabolic risk factors
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Omentin is an adipocytokine that is abundantly expressed in visceral fat tissue. We investigated the association of omentin with the number of metabolic risk factors. Finding: The study population comprised 201 Japanese men who underwent annual health checkups. Plasma omentin levels were determined by enzyme-linked immunosorbent assay. We divided the subjects into 4 groups according to omentin levels. A reduction of plasma omentin levels significantly correlated with an increase in the mean number of metabolic risk factors such as increased waist circumference, dyslipidemia, high blood pressure and glucose intolerance. Conclusions: Circulating omentin levels negatively correlated with the multiplicity of metabolic risk factors, suggesting that omentin acts as a biomarker of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625 · cited 3×
“Accumulating evidence indicates that adipose tissue is an active endocrine organ that produces various bioactive substances, also known as adipocytokines or adipokines [4,5].”
BackgroundSelf-citationAbdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 2×
“Individuals with excess of visceral fat accumulation have a high risk of the development of metabolic syndrome [3].”
BackgroundOverweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease
Matsuzawa, Y. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0380 · Cited by 434 · cited 2×
“Accumulating evidence indicates that adipose tissue is an active endocrine organ that produces various bioactive substances, also known as adipocytokines or adipokines [4,5].”
BackgroundTan, B. K., Adya, R., Farhatullah, S., Lewandowski, K. C., O’Hare, P., Lehnert, H., & Randeva, H. S. (2008) · Diabetes · doi:10.2337/db07-0990 · Cited by 273 · cited 1×
“Omentin is also down-regulated in association with obesity-linked metabolic disorders including insulin resistance, glucose intolerance and type 2 diabetes [12-14].”
Background
Cited by
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Fuster, J. J., Ouchi, N., Gokce, N., & Walsh, K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306885 · Cited by 664
Self-citationAdipose tissue, obesity and adipokines: role in cancer promotion
Booth, A., Magnuson, A., Fouts, J., & Foster, M. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0037 · Cited by 329
Role of anti-inflammatory adipokines in obesity-related diseases
Ohashi, K., Shibata, R., Murohara, T., & Ouchi, N. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.03.009 · Cited by 319
Self-citationThe impact of aging on adipose function and adipokine synthesis
Mancuso, P., & Bouchard, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00137 · Cited by 314
Metadata
- Authors
- Shibata, R., Ouchi, N., Takahashi, R., Terakura, Y., Ohashi, K., Ikeda, N., Higuchi, A., Terasaki, H., Kihara, S., & Murohara, T.
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2012-07-26
- Volume
- 4
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1758-5996 (ISSN-L)
- OpenAlex
- W2163950496
- Cited by
- 134
- References
- 5
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omentin as a novel biomarker of metabolic risk factors. https://app.cochat.ai/papers/10.1186/1758-5996-4-37
- The paper
- Shibata, R., Ouchi, N., Takahashi, R., Terakura, Y., Ohashi, K., Ikeda, N., Higuchi, A., Terasaki, H., Kihara, S., & Murohara, T. (2012). Omentin as a novel biomarker of metabolic risk factors. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/1758-5996-4-37
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.